1. Table of Contents
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Primary Sclerosing Cholangitis Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Primary Sclerosing Cholangitis Clinical Trials by Region
2.2.2 Average Enrollment of Primary Sclerosing Cholangitis Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Primary Sclerosing Cholangitis Treatment, 2019

3. Region wise Primary Sclerosing Cholangitis Clinical Trials
3.1 Asia Pacific Primary Sclerosing Cholangitis Clinical Trials by Country
3.2 Europe Primary Sclerosing Cholangitis Clinical Trials by Country
3.3 North America Primary Sclerosing Cholangitis Clinical Trials by Country
3.4 Middle East and Africa Primary Sclerosing Cholangitis Clinical Trials by Country
3.5 South and Central America Primary Sclerosing Cholangitis Clinical Trials by Country

4. Primary Sclerosing Cholangitis Clinical Trial Trends
4.1 Start Year wise Primary Sclerosing Cholangitis Clinical Trials
4.2 Phase wise Primary Sclerosing Cholangitis Clinical Trials
4.3 Trial Status wise Primary Sclerosing Cholangitis Clinical Trials
4.4 Trial Type wise Primary Sclerosing Cholangitis Clinical Trials

5. Primary Sclerosing Cholangitis Average Enrollment Trends
5.1 Average Enrollment in Primary Sclerosing Cholangitis Trials by Year
5.2 Average Enrollment in Primary Sclerosing Cholangitis Trials by Phase
5.3 Average Enrollment in Primary Sclerosing Cholangitis Trials by Status
5.4 Average Enrollment in Primary Sclerosing Cholangitis Trials by Type of Trial

6. Companies Participating in Primary Sclerosing Cholangitis Clinical Trials
6.1 Primary Sclerosing Cholangitis Trials by Sponsor Type
6.2 Primary Sclerosing Cholangitis Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Primary Sclerosing Cholangitis Trials- Phase 1
7.2 Primary Sclerosing Cholangitis Trials- Phase 2
7.3 Primary Sclerosing Cholangitis Trials- Phase 3
7.4 Primary Sclerosing Cholangitis Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Primary Sclerosing Cholangitis Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Primary Sclerosing Cholangitis Clinical Trials and Enrolment
Figure 5: Europe – Country wise Primary Sclerosing Cholangitis Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Primary Sclerosing Cholangitis Clinical Trials and Enrolment
Figure 7: North America – Country wise Primary Sclerosing Cholangitis Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Primary Sclerosing Cholangitis Clinical Trials and Enrolment
Figure 9: Primary Sclerosing Cholangitis Clinical Trials by Phase
Figure 10: Primary Sclerosing Cholangitis Clinical Trials by Trial Status
Figure 11: Primary Sclerosing Cholangitis Clinical Trials by Type
Figure 12: Primary Sclerosing Cholangitis Clinical Trials by Sponsor Type
Figure 13: Primary Sclerosing Cholangitis Clinical Trials by Leading Sponsors
Figure 14: Primary Sclerosing Cholangitis Average Enrollment by Phase
Figure 15: Primary Sclerosing Cholangitis Average Enrollment by Trial Status
Figure 16: Primary Sclerosing Cholangitis Average Enrollment by Type
Figure 17: Primary Sclerosing Cholangitis- Average Enrolment by Type of Sponsors
Figure 18: Primary Sclerosing Cholangitis- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List of Tables
Table 1: Primary Sclerosing Cholangitis Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Primary Sclerosing Cholangitis Clinical Trials and Enrolment
Table 5: Europe – Country wise Primary Sclerosing Cholangitis Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Primary Sclerosing Cholangitis Clinical Trials and Enrolment
Table 7: North America – Country wise Primary Sclerosing Cholangitis Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Primary Sclerosing Cholangitis Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Primary Sclerosing Cholangitis Average Enrollment by Phase
Table 15: Primary Sclerosing Cholangitis Average Enrollment by Trial Status
Table 16: Primary Sclerosing Cholangitis Average Enrollment by Type
Table 17: Primary Sclerosing Cholangitis- Average Enrolment by Type of Sponsors
Table 18: Primary Sclerosing Cholangitis- Enrolment by Leading Sponsors

Companies mentioned
Acorda Therapeutics Inc, Allergan Plc, Axcan Pharma Inc, Celgene Corp, ChemoCentryx Inc, ChemomAb Ltd, Dr. Falk Pharma GmbH, Gilead Sciences Inc, Hightide Biopharma Pty Ltd, Shire Plc